<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663582</url>
  </required_header>
  <id_info>
    <org_study_id>SHP633-306</org_study_id>
    <nct_id>NCT03663582</nct_id>
  </id_info>
  <brief_title>Study of Teduglutide in Japanese Participants With Short Bowel Syndrome</brief_title>
  <official_title>A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical study are to evaluate the safety, efficacy, and&#xD;
      pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS)&#xD;
      who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2018</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in weekly PS volume at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Percent change from baseline in weekly PS volume at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in days per week of PS at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)</measure>
    <time_frame>Week 24/EOT</time_frame>
    <description>Number of participants who were completely weaned off PS at Week 24/EOT was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>AUC0-t of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>Cmax of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>Tmax of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-phase Half-life (T1/2) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>T1/2 of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>CL/F of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Teduglutide</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
    <description>Vz/F of teduglutide was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to EOT/ET (up to Week 28)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>From start of study drug administration up to EOT/ET (up to Week 28)</time_frame>
    <description>12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in pulse rate at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in body temperature at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in hemoglobin at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in hematocrit at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in serum blood urea nitrogen at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in creatinine at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in urine sodium at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>EOT/ET (up to Week 28)</time_frame>
    <description>Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in 48-hour urine output at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in body weight at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)</measure>
    <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
    <description>Change from baseline in BMI at EOT/ET was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)</measure>
    <time_frame>Week 24/ET</time_frame>
    <description>GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe</intervention_name>
    <description>Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle</intervention_name>
    <description>Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vial Adapter for Device</intervention_name>
    <description>Vial adapter for device is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to voluntarily provide written, signed, and informed consent to participate in&#xD;
             the study.&#xD;
&#xD;
          2. Male or female 16 years of age or older at the time of signing informed consent.&#xD;
&#xD;
          3. Intestinal failure due to short bowel syndrome (SBS) as a result of major intestinal&#xD;
             resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's&#xD;
             disease) that resulted in at least 12 continuous months of parenteral&#xD;
             nutrition/intravenous (PN/IV) dependence at the time of informed consent.&#xD;
&#xD;
          4. Parenteral nutrition requirement of at least 3 times per week during the week before&#xD;
             the screening visit and during the 2 weeks prior to the baseline visit.&#xD;
&#xD;
          5. Stable PN/IV requirement for at least 4 consecutive weeks immediately prior to the&#xD;
             start of teduglutide treatment. Stability is defined as: a. Actual PN/IV usage is&#xD;
             similar to prescribed PN/IV; b. Baseline (Visit 2) 48-hour oral fluid intake and urine&#xD;
             output (I/O) volumes fall within +/- 25 percent (%) of the respective 48-hour I/O&#xD;
             volumes at the last optimization visit; c. Urine output volume should NOT fall below 2&#xD;
             liter (L) and should not exceed 4 L per 48 hours at the last optimization visit, the&#xD;
             stabilization visit, and the baseline visit.&#xD;
&#xD;
          6. For participants with a history of Crohn's disease, clinical remission for at least 12&#xD;
             weeks prior to the baseline visit as demonstrated by clinical assessment, which may&#xD;
             include procedure-based evidence of remission.&#xD;
&#xD;
          7. Females of childbearing potential must agree to comply with the contraceptive&#xD;
             requirements of the protocol.&#xD;
&#xD;
          8. An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in a clinical study using an experimental drug within 30 days or 5.5&#xD;
             halflives, whichever is longer, prior to screening, or concurrent participation in any&#xD;
             other clinical study.&#xD;
&#xD;
          2. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these&#xD;
             hormones within the past 6 months.&#xD;
&#xD;
          3. Use of octreotide, GLP-1 analogs, dipeptidyl peptidase-IV inhibitors, or enteral&#xD;
             glutamine within 30 days.&#xD;
&#xD;
          4. Previous use of teduglutide.&#xD;
&#xD;
          5. Participants with active inflammatory bowel disease (IBD) or participants with IBD who&#xD;
             received a change in immunosuppressant therapy (example, azathioprine, anti- tumor&#xD;
             necrosis factor (TNFs)) within the past 6 months.&#xD;
&#xD;
          6. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis,&#xD;
             microvillus inclusion disease, familial adenomatous polyposis, etc.&#xD;
&#xD;
          7. Chronic intestinal pseudo-obstruction or severe dysmotility.&#xD;
&#xD;
          8. Clinically significant intestinal stenosis or obstruction, or evidence of such on&#xD;
             upper gastrointestinal (GI) series with small bowel follow-through, within the past 6&#xD;
             months.&#xD;
&#xD;
          9. Major GI surgical intervention, including bowel lengthening procedures, within the&#xD;
             past 3 months (insertion of feeding tube or endoscopic procedure is allowed).&#xD;
&#xD;
         10. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or&#xD;
             congenital heart disease).&#xD;
&#xD;
         11. Moderate or severe renal impairment, defined as creatinine clearance less than (&lt;) 50&#xD;
             millilitre (ml)/ minute (min).&#xD;
&#xD;
         12. Currently diagnosed with cancer or a history of any cancer except surgically curative&#xD;
             skin cancer within the past 5 years.&#xD;
&#xD;
         13. Severe hepatobiliary disease including: a. Total bilirubin level greater than or equal&#xD;
             to (&gt;=) 2 times the upper limit of normal (ULN); b. Aspartate aminotransferase (AST)&#xD;
             &gt;=5 times ULN; c. Alanine aminotransferase (ALT) &gt;=5 times ULN.&#xD;
&#xD;
         14. Active clinically significant pancreatic disease, including clinical signs of&#xD;
             pancreatitis associated with elevations in serum amylase or lipase &gt;=2 times ULN.&#xD;
&#xD;
         15. More than 4 SBS-related or PN/IV-related hospital admissions (example, central line&#xD;
             associated bloodstream infection, bowel obstruction, severe fluid/electrolyte&#xD;
             disturbances) within the past 12 months.&#xD;
&#xD;
         16. Unscheduled hospitalization within 30 days prior to screening.&#xD;
&#xD;
         17. Pregnant or lactating female.&#xD;
&#xD;
         18. Any condition or circumstance that in the investigator's opinion put the participant&#xD;
             at any undue risk, prevent completion of the study, or interfere with analysis of the&#xD;
             study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi-Ken</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>July 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, …).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03663582/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03663582/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 5 sites in Japan between 06 July 2018 (first participant first visit) and 06 August 2019 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 7 participants were enrolled and received the treatment. Out of them, 6 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Teduglutide</title>
          <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants in the intent-to-treat (ITT) population who received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Teduglutide</title>
          <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in weekly PS volume at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in weekly PS volume at EOT/ET was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Liter per week (L/Week)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="3.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Percent change from baseline in weekly PS volume at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Percent change from baseline in weekly PS volume at EOT/ET was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.19" spread="24.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20</title>
        <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.</description>
        <time_frame>Baseline, Week 20</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit. Here, number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20</title>
          <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit. Here, number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24</title>
        <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit. Here, number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24</title>
          <description>Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit. Here, number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in days per week of PS at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in days per week of PS at EOT/ET was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Days per Week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Micromoles (mcmol)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.973" spread="11.7309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)</title>
        <description>Number of participants who were completely weaned off PS at Week 24/EOT was reported.</description>
        <time_frame>Week 24/EOT</time_frame>
        <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)</title>
          <description>Number of participants who were completely weaned off PS at Week 24/EOT was reported.</description>
          <population>ITT population included all participants who were deemed eligible for teduglutide treatment at the baseline visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weaned Off Parenteral Support: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weaned Off Parenteral Support: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide</title>
        <description>AUC0-t of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>Pharmacokinetic (PK) population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide</title>
          <description>AUC0-t of teduglutide was reported.</description>
          <population>Pharmacokinetic (PK) population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
          <units>Hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.3" spread="80.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Teduglutide</title>
        <description>Cmax of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Teduglutide</title>
          <description>Cmax of teduglutide was reported.</description>
          <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.50" spread="16.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Teduglutide</title>
        <description>Tmax of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Teduglutide</title>
          <description>Tmax of teduglutide was reported.</description>
          <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.87" upper_limit="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal-phase Half-life (T1/2) of Teduglutide</title>
        <description>T1/2 of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal-phase Half-life (T1/2) of Teduglutide</title>
          <description>T1/2 of teduglutide was reported.</description>
          <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.751" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance (CL/F) of Teduglutide</title>
        <description>CL/F of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) of Teduglutide</title>
          <description>CL/F of teduglutide was reported.</description>
          <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
          <units>Milliliter per hour (mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10858.9" spread="4038.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F) of Teduglutide</title>
        <description>Vz/F of teduglutide was reported.</description>
        <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12</time_frame>
        <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) of Teduglutide</title>
          <description>Vz/F of teduglutide was reported.</description>
          <population>PK population included all participants who received at least 1 dose of teduglutide and had at least 1 evaluable post-dose pharmacokinetic concentration value. Here, the number of participants analyzed refer to the number of participants evaluable for this outcome measure.</population>
          <units>Milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17167.4" spread="8371.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.</description>
        <time_frame>From start of study drug administration up to EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)</title>
        <description>12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.</description>
        <time_frame>From start of study drug administration up to EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)</title>
          <description>12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Millimetre of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure: EOT (up to Week 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure: EOT (up to Week 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in pulse rate at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in pulse rate at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Beats per minute (beats/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in body temperature at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in body temperature at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in hemoglobin at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in hemoglobin at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Gram per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in hematocrit at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in hematocrit at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Volume per volume (v/v)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in serum blood urea nitrogen at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in serum blood urea nitrogen at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in creatinine at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in creatinine at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Micromoles per liter (mcmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in urine sodium at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in urine sodium at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="64.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.</description>
        <time_frame>EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in 48-hour urine output at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in 48-hour urine output at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Milliliter per day (mL/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.57" spread="242.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in body weight at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in body weight at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="1.1146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)</title>
        <description>Change from baseline in BMI at EOT/ET was reported.</description>
        <time_frame>Baseline, EOT/ET (up to Week 28)</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)</title>
          <description>Change from baseline in BMI at EOT/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)</title>
        <description>GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.</description>
        <time_frame>Week 24/ET</time_frame>
        <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Teduglutide</title>
            <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)</title>
          <description>GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.</description>
          <population>Safety population included all participants in the ITT population who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to EOT/ET (up to Week 28)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Teduglutide</title>
          <description>Participants received 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypozincaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

